<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="utf-8">

    <title>Notitia | Pipeline</title>
    <meta name="description" content="Homepage for NotitiaBio">
    <meta name="author" content="Notitia">

    <link rel="stylesheet" href="style.css">
    <link rel="icon" href="images/small-logo.png" type="image/png">
</head>
<nav class="sidenav">
    <img src="images/Original-on-transparent.png" alt="notitia logo">
    <a href="index.html" >Home</a>
    <a href="about.html">About us</a>
    <a href="science.html">Our Science</a>
    <a href="#" class="active">Pipeline</a>
    <a href="investors.html">Investor & News</a>
</nav>
<main>
    <section class="hero pipeline-hero">
        <h1>Our Pipeline</h1>
    </section>

    <section class="pipeline">
        <h1>Clinical Trial Progress</h1>
        <h4>NM108</h4>
        <div class="progress">
            <div class="progress-bar pipe-1" role="progressbar" style="width: 25%" aria-valuenow="15" aria-valuemin="0"
                aria-valuemax="100"></div>
            <div class="progress-bar pipe-2" role="progressbar" style="width: 25%" aria-valuenow="30" aria-valuemin="0"
                aria-valuemax="100"></div>
            <div class="progress-bar pipe-3" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
                aria-valuemax="100"></div>
            <div class="progress-bar pipe-4" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
            aria-valuemax="100"></div>
        </div>
        <p class="nm108">
            NBT-NM108 is an investigational, oral, high-fiber nutrient-mix drink for the treatment of COVID-19 and other respiratory viral infections in patients with type 2 diabetes (T2D) and prediabetes. The FDA has allowed the product to be tested in a phase 2a clinical trial to assess its efficacy in diabetic and prediabetic COVID-19 patients.

Mechanism of Action

NBT-NM108’s proprietary formula contains nutrients that can support the growth of the Foundation Guild bacteria and, in turn, suppress the pathogens that are responsible for secondary complications.

The use of this product will reduce symptom severity, lower the needs of hospitalization, and reduce the risk of sepsis in patients with pre-existing conditions. 

Unmet Need in COVID-19

Currently, there are no treatments available for high-risk patients that can decrease the rate of complications and reduce hospitalizations while the patients are still in home isolation. 

High-risk COVID-19 patients with pre-existing conditions such as T2D, prediabetes, and obesity, have an over-growth of endotoxin producing pathogens in the gut. These dangerous pathogens could potentially aggravate inflammation and induce sepsis and other secondary complications if translocated across the gut epithelium to internal organs.

Over 62% of hospitalized COVID-19 patients exhibit digestive symptoms such as diarrhea, vomiting, and abdominal pain. SARS-CoV-2 virus particles have also been cultured from patient’s fecal samples. All this evidence indicates that gut viral infection in COVID-19 patients is common. Gut infections damage the gut epithelium cells and make the gut “leaky”. Thus, the over-growing endotoxin producers would translocate through the “leaky” gut and worsen symptoms and induce secondary complications that require hospitalization and elevate mortality.

NBT-NM108 is designed to decrease the rate of complications and reduce hospitalizations in high-risk COVID-19 patients by suppressing the pathogens in the body through supporting the Foundation Guild in the gut microbiome. 
  
Status of Clinical Program

Notitia is evaluating the efficacy of NBT-NM108 in a phase 2a clinical study in COVID-19 patients with type 2 diabetes and prediabetes. You can learn more about our on-going clinical trials here. 
        </p>

        <h4>LP306</h4>
        <div class="progress">
            <div class="progress-bar pipe-1" role="progressbar" style="width: 25%" aria-valuenow="15" aria-valuemin="0"
                aria-valuemax="100"></div>
            <div class="progress-bar pipe-2" role="progressbar" style="width: 25%" aria-valuenow="30" aria-valuemin="0"
                aria-valuemax="100"></div>
                <div class="progress-bar pipe-3 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
                aria-valuemax="100"></div>
            <div class="progress-bar pipe-4 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
            aria-valuemax="100"></div>
        </div>

        <h4>Name tbd</h4>
        <div class="progress">
            <div class="progress-bar pipe-1" role="progressbar" style="width: 25%" aria-valuenow="15" aria-valuemin="0"
                aria-valuemax="100"></div>
                <div class="progress-bar pipe-2 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="30" aria-valuemin="0"
                aria-valuemax="100"></div>
                <div class="progress-bar pipe-3 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
                aria-valuemax="100"></div>
            <div class="progress-bar pipe-4 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
            aria-valuemax="100"></div>
        </div>

        <h4>name tbd</h4>
        <div class="progress">
            <div class="progress-bar pipe-1" role="progressbar" style="width: 25%" aria-valuenow="15" aria-valuemin="0"
                aria-valuemax="100"></div>
                <div class="progress-bar pipe-2 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="30" aria-valuemin="0"
                aria-valuemax="100"></div>
                <div class="progress-bar pipe-3 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
                aria-valuemax="100"></div>
            <div class="progress-bar pipe-4 pipe-gray" role="progressbar" style="width: 25%" aria-valuenow="20" aria-valuemin="0"
            aria-valuemax="100"></div>
        </div>

    </section>

    <footer>
        Copyright &copy; 2021 Notitia Biotechnologies. All Rights Reserved.
    </footer>
    <script src="https://code.jquery.com/jquery-3.5.1.slim.min.js"
        integrity="sha256-4+XzXVhsDmqanXGHaHvgh1gMQKX40OUvDEBTu8JcmNs=" crossorigin="anonymous"></script>
    <script src="jquery-3.5.1.min.js"></script>
</main>

</html>